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1. Macrophages and DCs play a critical role in leishmaniasis disease.
2. Cytokine patterns lead with different disease outcomes.
3. The effective mechanisms for parasite killing are the production of NO, ROS and lysosomal proteases.
4. Leishmania uses a variety of evasion mechanisms to favor its survival and replication in macrophages.
5. Current treatments to leishmaniasis include the use of drugs, but their side effects are high.
6. Immunotherapy is a promising alternative to conventional drugs, but its use is controversial and further study is needed.
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Macrophages are indispensable for parasite survival, replication and differentiation. Appropriate activation
of macrophages is crucial for eliminating the pathogen. The activation is divided into classical and alternative
activation. [2]
Parasites of the genus Leishmania are the causative agents of cutaneous, mucocutaneous or
visceral leishmaniasis. This disease is considered endemic in over 90 countries and about 2 million
new cases occur every year. More than 12 million people are believed to be infected, 310 million
people are at risk and around 20 to 50 thousand deaths annually are due to the disease. [1]
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TLR2  recognizes LPG and amastigote-specific
antigens.
TLR4  recognizes GSLP and P8GLC
Figure 2: Dendritic cells and macrophages regulate the outcome of Leishmania
infection.
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Figure 1: Life cycle of Leishmania. 
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Promastigotes
TNF-α, IL-12, IFN-
γ, NO, ROS [3]
Gp63  binds to fibronectin receptors.
Parasite adhesion and internalization [4, 5]
Amastigotes
IgG-coated parasites bind to 
FcγR
Evasion mechanisms
Surviving in the Phagosome Consequence
Acid phosphatases Inhibits the attack of superoxide and hydroxyl radicals
Proton pump Resist attack of acidic enzymes, maintaining pH close to neutral
LPG Inhibits lysosomal enzymes. Inhibits respiratory burst 
Iron transporters LIT1 and LIT2 Counteracts Nramp1 functions. Compete with the host’s iron 
sequestering mechanism. 
Arginase Attenuates iNOS, facilitates growth (polyamine pathway)
Treatments
Conclusions
Treatment Function
Classical drugs
Pentavalent antimonials [7] Induction of ROS and NO 
production.  Upregulation of IFN-γ
receptors. IL-12 production
Miltefosine [8] Enhance IFN-γ receptors. Induce IL-
12-dependent Th1 response and 
reverse Th2 to Th1 response. 
Immunotherapy
Cytokine immunotherapy [9] Treatment with IL-12 or neutralizing
antibody to IL-4  reverses 
nonhealing disease phenotype
Figure 3: Leishmania-induced host phosphatase activation.
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Alteration of Toll-Like Receptor Pathways Consequence
Suppressors of SOCS-1 and SOCS-3 Negatively regulates TLR2 induced cytokine induction
Activation of host ubiquitinating editing 
enzyme A20
Impairment of TLR2-mediated release of IL-12 and TNF-α
Activation of SHP-1 Inhibits interaction with TRAF6 and further induction of NO, IL-12 
and TNF-α
Inhibitors of serine protease (ISP) Prevent TLR4 activation
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Figure 4: Modification of the Complement 
System by GP63.
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